Thiogenesis Therapeutics (TSXV:TTI) Common Stock : C$15.67 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Common Stock?

Thiogenesis Therapeutics's quarterly common stock stayed the same from Mar. 2024 (C$15.66 Mil) to Jun. 2024 (C$15.66 Mil) but then increased from Jun. 2024 (C$15.66 Mil) to Sep. 2024 (C$15.67 Mil).

Thiogenesis Therapeutics's annual common stock increased from Feb. 2021 (C$0.27 Mil) to Feb. 2022 (C$0.30 Mil) and increased from Feb. 2022 (C$0.30 Mil) to Dec. 2023 (C$15.01 Mil).

Thiogenesis Therapeutics Common Stock Historical Data

The historical data trend for Thiogenesis Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Common Stock Chart

Thiogenesis Therapeutics Annual Data

Trend

Dec19

Dec20

Feb21

Feb22

Dec23

Common Stock

0.59

0.27

0.30

15.01

Thiogenesis Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial											11.13	15.01	15.66	15.66	15.67

Thiogenesis Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Thiogenesis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

TTIPF:USA Q8M:Germany

Address

4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6

Website

https://www.thiogenesis.com

Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.

Executives

Vincent P. Stanton

10% Security Holder